Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVXL Anavex Life Sciences	$9.50 -1.3%	$8.85	$3.51 ▼ $14.44	$808.11M	0.8	1.23 million shs	638,982 shs
BCAX Bicara Therapeutics	$14.37 -3.4%	$12.87	$8.91 ▼ $28.09	$783.50M	N/A	476,880 shs	584,055 shs
CMRX Chimerix	$8.54	$8.00	$0.75 ▼ $8.55	$801.09M	-0.17	2.30 million shs	N/A
OCGN Ocugen	$0.75 +2.7%	$0.65	$0.52 ▼ $2.06	$218.19M	3.78	4.67 million shs	2.67 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVXL Anavex Life Sciences	-1.35%	+2.04%	+10.72%	-0.73%	+160.27%
BCAX Bicara Therapeutics	-3.43%	-7.35%	+10.28%	+11.31%	+1,436,999,900.00%
CMRX Chimerix	0.00%	0.00%	+0.35%	+107.79%	+808.51%
OCGN Ocugen	+2.65%	+3.63%	+5.24%	-2.86%	-43.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVXL Anavex Life Sciences	3.7975 of 5 stars	3.7	1.0	0.0	4.7	2.8	0.8	0.6
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	3.0234 of 5 stars	1.0	4.0	0.0	4.1	2.9	2.5	0.6
OCGN Ocugen	1.0093 of 5 stars	3.5	0.0	0.0	0.0	2.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVXL Anavex Life Sciences	3.33	Buy	$44.00	363.16% Upside
BCAX Bicara Therapeutics	2.89	Moderate Buy	$32.43	125.68% Upside
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
OCGN Ocugen	3.00	Buy	$6.33	747.61% Upside

Current Analyst Ratings Breakdown

Latest OCGN, BCAX, AVXL, and CMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/7/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
4/7/2025	AVXL Anavex Life Sciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$46.00 ➝ $46.00
4/7/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $44.00
3/31/2025	AVXL Anavex Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
3/27/2025	BCAX Bicara Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$48.00
3/27/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$31.00
3/13/2025	BCAX Bicara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$13.01 ➝ $13.01
3/6/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/6/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
3/5/2025	CMRX Chimerix	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$10.00 ➝ $8.50

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	$1.42 per share	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
OCGN Ocugen	$4.06M	53.81	N/A	N/A	$0.16 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVXL Anavex Life Sciences	-$43M	-$0.55	N/A	N/A	N/A	N/A	-37.50%	-34.08%	5/8/2025 (Estimated)
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	5/7/2025 (Estimated)
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	5/13/2025 (Estimated)

Latest OCGN, BCAX, AVXL, and CMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OCGN Ocugen	-$0.06	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q2 2025	AVXL Anavex Life Sciences	-$0.16	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	CMRX Chimerix	-$0.27	N/A	N/A	N/A	N/A	N/A
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/21/2025	Q4 2024	CMRX Chimerix	-$0.26	-$0.25	+$0.01	-$0.25	$0.31 million	$0.06 million
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million
2/12/2025	Q1 2025	AVXL Anavex Life Sciences	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVXL Anavex Life Sciences	N/A	N/A	N/A	N/A	N/A
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVXL Anavex Life Sciences	N/A	9.45	9.45
BCAX Bicara Therapeutics	N/A	N/A	N/A
CMRX Chimerix	N/A	6.33	6.33
OCGN Ocugen	0.04	2.58	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVXL Anavex Life Sciences	31.55%
BCAX Bicara Therapeutics	N/A
CMRX Chimerix	45.42%
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
AVXL Anavex Life Sciences	11.00%
BCAX Bicara Therapeutics	N/A
CMRX Chimerix	13.10%
OCGN Ocugen	4.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVXL Anavex Life Sciences	40	85.06 million	75.71 million	Optionable
BCAX Bicara Therapeutics	32	54.52 million	N/A	N/A
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
OCGN Ocugen	80	292.01 million	278.82 million	Optionable

OCGN, BCAX, AVXL, and CMRX Headlines

Recent News About These Companies

Contrasting Ocugen (NASDAQ:OCGN) & Lexeo Therapeutics (NASDAQ:LXEO)

April 30 at 2:27 AM | americanbankingnews.com

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

April 29 at 7:30 AM | globenewswire.com

Renaissance Technologies LLC Invests $1.68 Million in Ocugen, Inc. (NASDAQ:OCGN)

April 29 at 3:42 AM | marketbeat.com

Ocugen Inc. stock rises Tuesday, still underperforms market

April 23, 2025 | marketwatch.com

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?

April 17, 2025 | msn.com

Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean

April 10, 2025 | msn.com

Ocugen management to meet with Maxim

April 9, 2025 | markets.businessinsider.com

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

April 8, 2025 | globenewswire.com

Stargardt Disease Market Predicted to See Upsurge Through 2034, Highlights DelveInsight | Acucela, Astellas Pharma, Alkeus Pharma

April 7, 2025 | theglobeandmail.com

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

March 21, 2025 | ophthalmologytimes.com

Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200

March 19, 2025 | clinicaltrialsarena.com

Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results

March 19, 2025 | msn.com

Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial

March 18, 2025 | markets.businessinsider.com

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

March 18, 2025 | globenewswire.com

Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf

March 6, 2025 | financialpost.com

Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | seekingalpha.com

Ocugen reports Q4 EPS (5c), consensus (5c)

March 6, 2025 | markets.businessinsider.com

Ocugen (OCGN) Q4 2024 Earnings Call Transcript

March 6, 2025 | msn.com

Ocugen Reports Progress in Gene Therapy Trials

March 5, 2025 | tipranks.com

Ocugen, Inc. Reports Progress on Clinical Trials and FDA Alignment for OCU410ST in Stargardt Disease, Highlights Positive Long-Term Data for OCU400

March 5, 2025 | quiverquant.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCGN, BCAX, AVXL, and CMRX Company Descriptions

Anavex Life Sciences NASDAQ:AVXL

$9.50 -0.13 (-1.35%)

As of 04/30/2025 04:00 PM Eastern

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Bicara Therapeutics NASDAQ:BCAX

$14.37 -0.51 (-3.43%)

As of 04/30/2025 04:00 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)

As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Ocugen NASDAQ:OCGN

$0.75 +0.02 (+2.65%)

As of 04/30/2025 04:00 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time